ABOS · Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

1210-1220 Washington St., Newton, MA, 02465, United States
Biotechnology
Healthcare

Market Cap

15.62M

52 Wk Range

$0.19 - $3.60

Previous Close

$0.22

Open

$0.22

Volume

2,668,043

Day Range

$0.20 - $0.23

Enterprise Value

-36.81M

Cash

78.6M

Avg Qtr Burn

-26.65M

Insider Ownership

6.79%

Institutional Own.

67.64%

Qtr Updated

Sep 30th 2026